retatrutide type 2 diabetes phase 2 trial 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide – The New Weight

Cancer history or active malignancy concerns require clinician-guided review before GH-axis stimulation is considered

As demand for weight-loss drugs rises, states grapple with Medicaid coverage Some researchers question long-term cost savings for state programs Boxes of the diabetes drug Ozempic rest on a pharmacy counter

Blood Flow

Cathelicidins 3.5.1

Patients who rely on compounded semaglutide would lose access to treatment if the salt form distinction is used to prohibit compounding

Conquering the Queasiness: How to Handle Nausea on Your GLP-1 Journey If you are taking a GLP-1 (like semaglutide) or a GLP-1/GIP (like tirzepatide) medication, you might be experiencing a "love-hate" relationship: you love the weight loss results, but you hate the occasional wave of nausea